A5004216611- Autoimmune Neurological Disorders and Treatments
- Peripheral Neuropathies and Disorders
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Genetic Neurodegenerative Diseases
- Cellular transport and secretion
- Glioma Diagnosis and Treatment
- Pharmacological Receptor Mechanisms and Effects
- Myasthenia Gravis and Thymoma
- RNA regulation and disease
- Genetics and Neurodevelopmental Disorders
- Herpesvirus Infections and Treatments
- Chronic Lymphocytic Leukemia Research
- Polyomavirus and related diseases
- CNS Lymphoma Diagnosis and Treatment
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Cardiac tumors and thrombi
- Neurological Complications and Syndromes
- Coronary Artery Anomalies
- Cell Adhesion Molecules Research
- Sarcoidosis and Beryllium Toxicity Research
- SARS-CoV-2 and COVID-19 Research
- Neuroendocrine Tumor Research Advances
- Antifungal resistance and susceptibility
University of Florence
2020-2025
Inserm
2022-2025
Université Claude Bernard Lyon 1
2022-2025
Centre National de la Recherche Scientifique
2022-2025
Hospices Civils de Lyon
2021-2025
Bielefeld University
2024
Hôpital Pierre Wertheimer
2024
Centre de Recherche en Neurosciences de Lyon
2022-2024
Istituto delle Scienze Neurologiche di Bologna
2024
Odense University Hospital
2024
Abstract While the spectrum of neurological immune checkpoint inhibitor-related adverse events is expanding, patients’ outcomes are not well documented. This study aimed to assess immune-related and identify prognostic factors. All patients experiencing grade ≥2 identified at two clinical networks (French Reference Center for Paraneoplastic Neurological Syndromes, Lyon; OncoNeuroTox, Paris) over five years were included. Modified Rankin scores assessed onset, 6, 12, 18 months, last visit. A...
Anti-Hu are the most frequent antibodies in paraneoplastic neurological syndromes, mainly associated with an often limited stage small cell lung cancer. The clinical presentation is pleomorphic, frequently multifocal. Although predominant phenotypes well characterized, how different syndromes associate unclear. Likewise, no specific study assessed performance of new-generation CT and PET scanners for cancer screening these patients. Herein, we aimed to describe pattern a retrospective cohort...
Immune checkpoint inhibitor-related encephalitis (ICI-encephalitis) is not well characterised and diagnostic prognostic biomarkers are lacking. We aimed to comprehensively characterise ICI-encephalitis identify outcome predictors.
During the COVID-19 pandemic, myasthenia gravis (MG) patients have been identified as subjects at high risk of developing severe COVID-19, and thus were offered vaccination with priority. The lack direct data on safety tolerability SARS-CoV-2 vaccines in MG contributed to vaccine hesitancy. To address this issue, assessed a large cohort from two referral centers.Patients confirmed diagnosis, consecutively seen between October December 2021 centers, enrolled. Demographics, clinical...
Relapses occur in 15%-25% of patients with leucine-rich glioma-inactivated 1 antibody (LGI1-Ab) autoimmune encephalitis and may cause additional disability. In this study, we clinically characterized the relapses identified factors predicting their occurrence.
Anti-NMDA receptor (NMDAR) encephalitis is defined by the presence of antibodies (Abs) targeting NMDAR in CSF. This study aimed to determine prognostic value persistent CSF NMDAR-Abs during follow-up.This retrospective observational included patients diagnosed with anti-NMDAR French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis whom samples were obtained at diagnosis >4 months follow-up evaluate NMDAR-Ab persistence. Because tested different time...
Purpose of review Immune checkpoint inhibitors (ICI) may trigger immune-related adverse events which rarely affect the central nervous system (CNS-irAEs). Over past few years, cumulative data have led to characterization well defined syndromes with distinct cancer and antibody associations as different outcomes. Recent findings The most frequent CNS-irAE is encephalitis, includes three main groups: meningoencephalitis, a nonfocal syndrome usually responsive corticosteroids; limbic associated...
Introduction Mononeuritis multiplex is frequently related to vasculitic neuropathy and has been reported only sporadically as an adverse event of immune checkpoint inhibitors. Methods Case series three patients with mononeuritis multiplex—all mesothelioma—identified in the databases two French clinical networks (French Reference Center for Paraneoplastic Neurological Syndromes, Lyon; OncoNeuroTox, Paris; January 2015–October 2022) set up collect investigate n-irAEs on a nationwide level....
The clinical course and the risk of chronicity neurologic immune-related adverse events (n-irAEs) associated with immune checkpoint inhibitors (ICIs) are not well documented. This study aimed to characterize n-irAEs assess prevalence chronic events.
Abstract Anti-IgLON5 disease presents with diverse symptoms, whose severity can be measured by the anti-IgLON5 composite score (ICS). This study applied ICS to a retrospective cohort ( n = 52; median age 72 years, 63% male) diagnosed in French Reference Center on Autoimmune Encephalitis (2016–2024), aiming describe and clinical course, assess its potential predict mortality. At diagnosis, distribution (median 18) aligned previous publications correlated time diagnosis 19 months); all...
Patients with ongoing seizures are usually not allowed to drive. The prognosis for seizure freedom is favorable in patients autoimmune encephalitis (AIE) antibodies against NMDA receptor (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and the gamma-aminobutyric-acid B (GABA
To describe a case of post-immune checkpoint inhibitor (ICI) opsoclonus-myoclonus-ataxia syndrome (OMAS), with complete clinical remission after treatment.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, and the association with immune-related adverse events (irAEs) is well-established. However, cerebellar irAEs are poorly defined their relationship paraneoplastic disorders remains unclear. Our aim was (i) to characterize irAE; (ii) compare it ataxia (PCA). We performed a multicenter, retrospective, cohort study of patients developing new-onset, immune-mediated, isolated/predominant dysfunction after ICI administration....